Treatment with cemsidomide resulted in notable responses at multiple dose levels for patients with multiple myeloma ...

A promising target for rare liver cancer, a functional cure for multiple myeloma — and support for people with ovarian cancer.

Johnson & Johnson has generated evidence that the pace of oncology innovation is overwhelming physicians. | Johnson & Johnson ...

During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of ...

FREDERICK, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...

CAMBRIDGE, Mass., May 07, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for ...

Updated daily for the most current view of patient care, Truveta Data accelerates evidence generation by replacing costly ...

The global immunotoxins market was valued at USD 159.9 million in 2024 and is projected to expand at a compound annual growth ...

In January 2025, Cullinan announced that the pivotal Phase 2b portion of REZILIENT1 met the primary endpoint of overall response rate in patients with EGFR ex20ins NSCLC who have received prior ...

Thalassemia is a serious but preventable genetic blood disorder that affects the body’s ability to produce normal haemoglobin ...

The Congress of Neurological Surgeons (CNS) has updated its guidelines on using emerging therapies to treat metastatic brain ...

A global study suggests that using small molecule inhibitors followed by epigenetic modifiers may significantly improve ...